TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression

Trends in Immunology

Volumn 31, Issue 6, 2010, Pages 220-227

  Yang, Li ^a   Pang, Yanli ^a   Moses, Harold L ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD8 ANTIGEN; CHEMOKINE; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; FIBROBLAST; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INFLAMMATORY CELL; LEUKOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MOLECULAR MECHANICS; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTEIN FUNCTION; REVIEW; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; DISEASE PROGRESSION; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSFORMING GROWTH FACTOR BETA;

EID: 77953023274     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2010.04.002     Document Type: Review

References (86)

1. Bierie B., and Moses H.L. Tumour microenvironment : TGFβ: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6 7 (2006) 506-520
2. Massague J. TGFbeta in Cancer. Cell 134 2 (2008) 215-230
3. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 6958 (2003) 577-584
4. Nakao A., et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature 389 6651 (1997) 631-635
5. Hayashi H., et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 89 7 (1997) 1165-1173
6. Akhurst R.J., and Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol. 11 11 (2001) S44-S51
7. Markowitz S., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268 5215 (1995) 1336-1338
8. Xie W., et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 62 2 (2002) 497-505
9. Yang L., and Moses H.L. Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer?. Cancer Res. 68 22 (2008) 9107-9111
10. Pangas S.A., et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol. Cell Biol. 28 1 (2008) 248-257
11. Guasch G., et al. Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 12 4 (2007) 313-327
12. Watanabe T., et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344 16 (2001) 1196-1206
13. Bruna A., et al. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11 2 (2007) 147-160
14. Arteaga C.L. Inhibition of TGFbeta signaling in cancer therapy. Curr. Opin. Genet. Dev. 16 1 (2006) 30-37
15. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2 8 (2002) 584-593
16. Guise T.A., and Chirgwin J.M. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin. Orthop. Relat. Res. 415 Suppl (2003) S32-38
17. Roberts A.B., and Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl. Acad. Sci. U. S. A. 100 15 (2003) 8621-8623
18. Bierie B., and Moses H.L. Gain or loss of TGFbeta signaling in mammary carcinoma cells can promote metastasis. Cell Cycle 8 20 (2009) 3319-3327
19. Padua D., et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133 1 (2008) 66-77
20. Adorno M., et al. A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137 1 (2009) 87-98
21. Dupont S., et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 136 1 (2009) 123-135
22. Liu I.M., et al. TGFbeta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO J. 28 2 (2009) 88-98
23. Li M.O., et al. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24 (2006) 99-146
24. Gorelik L., and Flavell R.A. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2 1 (2002) 46-53
25. Li M.O., and Flavell R.A. TGF-beta: a master of all T cell trades. Cell 134 3 (2008) 392-404
26. Wahl S.M., et al. TGF-beta: a mobile purveyor of immune privilege. Immunol. Rev. 213 (2006) 213-227
27. Gorelik L., and Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7 10 (2001) 1118-1122
28. Thomas D.A., and Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8 5 (2005) 369-380
29. Trapani J.A. The dual adverse effects of TGF-beta secretion on tumor progression. Cancer Cell 8 5 (2005) 349-350
30. Nakamura K., et al. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194 5 (2001) 629-644
31. Ghiringhelli F., et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 202 8 (2005) 1075-1085
32. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30 5 (2009) 636-645
33. Bettelli E., et al. T(H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8 4 (2007) 345-350
34. Korn T., et al. IL-17 and Th17 cells. Annu. Rev. Immunol. 27 (2009) 485-517
35. Mangan P.R., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441 7090 (2006) 231-234
36. Veldhoen M., et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24 2 (2006) 179-189
37. Korn T., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448 7152 (2007) 484-487
38. Chen M.L., et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 2 (2005) 419-424
39. Kim B.G., et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 441 7096 (2006) 1015-1019
40. Castriconi R., et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 100 7 (2003) 4120-4125
41. Lee J.C., et al. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J. Immunol. 172 12 (2004) 7335-7340
42. Laouar Y., et al. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat. Immunol. 6 6 (2005) 600-607
43. Kopp H.G., et al. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 69 19 (2009) 7775-7783
44. Friese M.A., et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res. 64 20 (2004) 7596-7603
45. Kehrl J.H., et al. Transforming growth factor-beta suppresses human B lymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J. Immunol. 146 11 (1991) 4016-4023
46. Cazac B.B., and Roes J. TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo. Immunity 13 4 (2000) 443-451
47. Inoue S., et al. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 66 15 (2006) 7741-7747
48. Mauri C., and Ehrenstein M.R. The 'short' history of regulatory B cells. Trends Immunol. 29 1 (2008) 34-40
49. Yanaba K., et al. A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses. Immunity 28 5 (2008) 639-650
50. de Visser K.E., et al. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7 5 (2005) 411-423
51. Gabrilovich D.I., and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9 3 (2009) 162-174
52. Movahedi K., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity. Blood 111 8 (2008) 4233-4244
53. Yang L., et al. Abrogation of TGFbeta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13 1 (2008) 23-35
54. Yang L., et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6 4 (2004) 409-421
55. Condeelis J., and Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 2 (2006) 263-266
56. Mantovani A., et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 25 3 (2006) 315-322
57. Mantovani A., et al. Cancer-related inflammation. Nature 454 7203 (2008) 436-444
58. Pollard J.W. Trophic macrophages in development and disease. Nat. Rev. Immunol. 9 4 (2009) 259-270
59. Joyce J.A., and Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 9 4 (2009) 239-252
60. Biswas S.K., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kB and enhanced IRF-3/STAT1 activation). Blood 107 5 (2006) 2112-2122
61. Fridlender Z.G., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 16 3 (2009) 183-194
62. Mantovani A. The yin-yang of tumor-associated neutrophils. Cancer Cell 16 3 (2009) 173-174
63. Terabe M., et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198 11 (2003) 1741-1752
64. Du R., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13 3 (2008) 206-220
65. Bristow R.G., and Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat. Rev. Cancer 8 3 (2008) 180-192
66. Bierie B., et al. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res. 68 6 (2008) 1809-1819
67. Bierie B., et al. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J. Clin. Invest. 119 6 (2009) 1571-1582
68. Kitamura T., et al. SMAD4-deficient intestinal tumors recruit CCR1(+) myeloid cells that promote invasion. Nat. Genet. 39 4 (2007) 467-475
69. Lu S.L., et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev. 20 10 (2006) 1331-1342
70. Engle S.J., et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-deficient mice. Cancer Res. 62 22 (2002) 6362-6366
71. Lu S.L., et al. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 64 13 (2004) 4405-4410
72. Bhowmick N.A., et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 5659 (2004) 848-851
73. Monteleone G., et al. A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J. Biol. Chem. 279 6 (2004) 3925-3932
74. Maggio-Price L., et al. Helicobacter infection is required for inflammation and colon cancer in SMAD3-deficient mice. Cancer Res. 66 2 (2006) 828-838
75. Lu T., et al. Dose-dependent cross-talk between the transforming growth factor-beta and interleukin-1 signaling pathways. Proc. Natl. Acad. Sci. U. S. A. 104 11 (2007) 4365-4370
76. Balkwill F., and Coussens L.M. Cancer: an inflammatory link. Nature 431 7007 (2004) 405-406
77. Hiratsuka S., et al. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 8 12 (2006) 1369-1375
78. Kim S., et al. Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res. 68 24 (2008) 10247-10256
79. Terabe M., et al. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin. Cancer Res. 15 21 (2009) 6560-6569
80. Biswas S., et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J. Clin. Invest. 117 5 (2007) 1305-1313
81. Nam J.S., et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68 10 (2008) 3835-3843
82. Nam J.S., et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 68 10 (2008) 3915-3923
83. Fujita T., et al. Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types. Cancer Res. 69 12 (2009) 5142-5150
84. Almand B., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6 5 (2000) 1755-1766
85. Budhu A., et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10 2 (2006) 99-111
86. Galon J., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 5795 (2006) 1960-1964